About me
Dr. Chul Kim is an Associate Professor at Georgetown University with a focus on thoracic oncology. His goal as a thoracic medical oncologist is to introduce innovative cancer therapies into clinical practice, and he is devoted to formulating clinical trials aimed at promoting personalized cancer treatments.
Dr. Kim's academic journey began at the Sungkyunkwan University School of Medicine in Seoul, South Korea, where he graduated Summa Cum Laude. He furthered his studies at the Harvard School of Public Health, obtaining a Master’s degree in Public Health. His medical training continued at the University of Minnesota where he trained in internal medicine. Later, he became a clinical fellow in hematology and oncology at the National Cancer Institute (NCI) of the National Institutes of Health (NIH).
In 2018, Dr. Kim was honored with the Norman Rales Young Investigator Award from the Conquer Cancer Foundation of the American Society of Clinical Oncology (ASCO). In 2021, he received the John F. Potter, MD, Award from Georgetown Lombardi Comprehensive Cancer Center.
Dr. Kim has authored more than 60 articles in reputable peer-reviewed journals, including Lancet Oncology, JAMA Oncology, Journal of Thoracic Oncology, Journal for ImmunoTherapy of Cancer, and Clinical Cancer Research. Additionally, he has served as a reviewer for various journals such as Journal of Clinical Oncology, Clinical Lung Cancer, Lancet HIV, Lancet Haematology, and JCO Precision Oncology.
He is an active member of the American Society of Clinical Oncology and the International Association for the Study of Lung Cancer.
Driven by his commitment to patient care, Dr. Kim aims to provide the best possible treatment options for his patients. In his free time, he enjoys hiking, exploring diverse cuisines, and traveling with his wife and son.
Clinical areas of focus
- Adenocarcinoma Of Lung
- Biological Targeted Therapy
- Cancer Chemotherapy
- Cancer Immunotherapy
- Chemoradiation
- Lung Cancer
- Lung Metastasis
- Mesothelioma
- Non Small Cell Lung Cancer
- Pleural Cancer
- Pulmonary Nodule
- Small Cell Lung Cancer
- Thymoma
- Thymus Cancer
Conditions and procedures
Procedures I perform
- Biological Targeted Therapy
- Cancer Chemotherapy
- Cancer Immunotherapy
- Chemoradiation
Practice locations
Distance from Change LocationEnter your Location
3800 Reservoir Road Northwest Lombardi Cancer Center Washington, DC, 20007
202-444-2223Fax 202-444-1229
Insurance
MedStar Health accepts most major health insurance plans. If you are uncertain as to whether your individual health insurance plan is accepted at MedStar Health, please call your insurance company.
-
List of insurance plans we accept
- Aetna Open Choice (PPO)
- Aetna Medicare Advantage HMO & PPO Plans
- Innovation Health: Open POS Plus
- Innovation Health: Open POS II
- Aetna Managed Choice Open Access (POS)
- Aetna Choice POS & Choice POS II
- Innovation Health: POS Plus
- Aetna Managed Choice (POS)
- Innovation Health: POS
- Aetna Open HMO/Open HMO Option/Open EPO Plus
- Aetna HMO-Open Access/Select OA
- Aetna HealthFund/Health Network Option OA
- Innovation Health: HMO & EPO Plus
- Aetna Select HMO/HealthFund/Health Network
- Aetna HMO
- Innovation Health: Open Network Only Plus
- Aetna Elect Choice/ Open Access (POS)
- Innovation Health: Network Only Plus
- Aetna Elect Choice/ EPO (Aetna Health Fund)
- Cigna TotalCare (HMO D-SNP)
- Cigna Preferred Medicare
- Cigna Alliance Medicare (HMO) |
- Cigna Achieve Medicare (HMO C-SNP)
- Veterans Affairs Community Care Network (VA CCN)
- United Medicare Advantage DSNP District of Columbia
- United Student Resources
- United Select Plus (POS)
- United Select HMO - EPO/NPP
- United Options (PPO) (includes Empire PPO)
- United Golden Rule
- United GEHA (for all other states) Compass Rose
- D-SNP)
- I-SNP
- United Nursing Home Plan (C-SNP
- United Erickson Advantage Plans
- United Choice Plus
- United Choice
- United Mamsi Life & Health
- MedStar Family Choice DC Healthy Families
- MedStar Family Choice DC Healthcare Alliance
- United MD IPA Preferred (POS)
- United MD IPA (HMO)
- Kaiser Permanente Signature-Added Choice
- Kaiser Signature
- Kaiser HMO Plus and DHMO Plus Member
- Kaiser Select-Added Choice
- Kaiser Select
- Kaiser Medicare Plus
- Kaiser Medicare Advantage Signature and Select
- Kaiser Flexible Choice
- Kaiser Maryland Medicaid MCO
- HumanaChoice PPO
- HumanaChoice Honor’s plan PPO
- Health Services for Children with Special Needs (HSCSN)
- Cigna True Choice Plus Medicare (PPO)
- Cigna True Choice Medicare (PPO)
- Cigna POS/Network POS
- Cigna Indemnity
- Cigna POS Open Access & Open Access Plus
- Cigna Network Open Access
- Cigna HMO Open Access
- Cigna PPO and PPO Plus
- Cigna EPO
- Cigna Choice Fund PPO
- Choice Care Network/HUMANA (PPO)
- Beech Street PPO
- Anthem Plus BCBS of VA HealthKeepers Plus
- Anthem (POS & Open Access POS) BCBS of VA HealthKeepers
- Anthem HMO - BCBS of VA HealthKeepers
- Innovation Health: Indemnity
- Aetna Traditional Choice (PPO)
- Aetna Student Health Insurance
- Aetna Signature Administrator PPO/TPA
- Aetna Quality Point of Service (POS)
- Innovation Health: PPO
- Cigna HMO & Network (HMO)
- WellPoint Maryland - Maryland Health Choice
- WellPoint Maryland
- Virginia Premier
- Veterans Affairs Community Care Network
- UnitedHealthcare Individual Exchange Plans
- United Community Plan - Maryland Health Choice Program
- Private Health Care Systems (PHCS) (PPO)
- Police and Fire Clinic
- United Optimum Choice Preferred (POS) & OCI Direct (HMO)
- United Optimum Choice
- United Navigate
- United Core Essential (HMO)
- United Group Medicare Advantage Plans
- United AARP Medicare Complete
- Traditional Medicare Fee for Service
- Medicaid - Virginia
- Medicaid - Maryland
- Medicaid - District of Columbia
- Tricare for Life East
- Tricare Reserve Select
- Tricare East Select
- Tricare East Prime
- Maryland Point of Service Plan (MPOS)
- HealthyBlue PPO
- Federal Employee Program (Std/Basic PPO/Blue Focus)
- CareFirst NASCO
- CareFirst MedStar Select PPO
- CareFirst MedStar PPO
- CareFirst Maryland Indemnity or PPO
- CareFirst Group Medicare Advantage prescription drug benefit (PPO)
- CareFirst Group Medicare Advantage
- CareFirst BC/BS Advantage Core/Enhanced
- CareFirst Blue Card Program (Out-of-area BCBS plans)
- CareFirst Administrators
- CareFirst (NCA) Indemnity
- Carefirst BlueChoice Opt Out Plus Open Access (POS)
- Carefirst Healthy Blue (HMO/POS)
- Carefirst BlueChoice Opt Out Open Access
- Carefirst BlueChoice Open Access
- Carefirst BlueChoice HMO
- Carefirst EPO
- Carefirst Blue Preferred PPO
- Coventry Health Care National Network PPO
- MedStar Family Choice - Maryland Health Choice
- First Health PPO
- Coventry of Delaware HMO/PPO
- Coventry Health Care of Virginia
- Great-West Healthcare POS/CIGNA
Education
Board Certification: American Board of Internal Medicine, Internal Medicine
Fellowship: National Institutes of Health (2017)
Residency: National Institutes of Health (2017)
Residency: University of Minnesota (2014)
Medical School: Sungkyunkwana University (2007)
Hospital affiliations
News and publications
https://www.cbsnews.com/news/fda-looks-to-help-more-cancer-patients-access-experimental-drugs-compassionate-use/
https://undark.org/2018/09/10/fda-drugs-accelerated-approval/
https://thetranslationalscientist.com/disease-area/proving-the-worth-of-icis
https://www.healio.com/news/hematology-oncology/20190208/immune-checkpoint-inhibitors-benefit-patients-with-hiv-advanced-cancer
Original papers in refereed journals
1. Yeung V, Kim C, Kiedrowski LA, Liu SV, Reuss JE. Use of on-therapy ctDNA monitoring in a patient with KIF5B-RET fusion positive advanced non-small cell lung cancer: a case report. Translational Lung Cancer Research. 2022;11(1):111.
2. Williams RM, Kareff SA, Sackstein P, Roy T, Luta G, Kim C, Taylor KL, Tammemagi MC. Race & sex disparities related to low-dose computed tomography lung cancer screening eligibility criteria: A lung cancer cases review. Lung Cancer. 2022;169:55-60. Epub 2022/06/02. doi: 10.1016/j.lungcan.2022.05.008. PubMed PMID: 35644087; PMCID: PMC9248363.
3. Wilgucki M, Yeung V, Ho G, Bravo Montenegro GL, Jones G, Reuss JE, Liu SV, Kim C. Osimertinib and Capmatinib Combination Therapy to Overcome MET Y1003N-Mediated Resistance in EGFR-Mutant NSCLC: A Case Report. JTO Clin Res Rep. 2022;3(10):100396. Epub 2022/10/04. doi: 10.1016/j.jtocrr.2022.100396. PubMed PMID: 36188633; PMCID: PMC9516460.
4. Sirgi Y, Krochmal R, Fleury CM, Holmes M, Dewitt CA, Cardis M, Kim C. Pembrolizumab-Associated Cutaneous and Pulmonary Sarcoidosis in Non-Small Cell Lung Cancer Treatment. Clin Lung Cancer. 2022. Epub 2022/06/15. doi: 10.1016/j.cllc.2022.05.011. PubMed PMID: 35701321.
5. Kim SY, Yin J, Bohlman S, Walker P, Dacic S, Kim C, Khan H, Liu SV, Ma PC, Nagasaka M. Characterization of MET Exon 14 Skipping Alterations (METex14) in Non-Small Cell Lung Cancer (NSCLC) and Identification of Potential Therapeutic Targets using Whole Transcriptome Sequencing (WTS). JTO Clinical and Research Reports. 2022:100381.
6. Joshi I, Peravali M, Geng X, Rao S, Chen KY, Veytsman I, Giaccone G, Liu SV, Kim C. Impact of Baseline Clinical Biomarkers on Treatment Outcomes in Patients With Advanced NSCLC Receiving First-line Pembrolizumab-Based Therapy. Clin Lung Cancer. 2022;23(5):438-45. Epub 2022/06/02. doi: 10.1016/j.cllc.2022.03.010. PubMed PMID: 35649819.
7. Zhang D, Tailor TD, Kim C, Atkins MB, Braithwaite D, Akinyemiju T. Immunotherapy Utilization Among Patients With Metastatic NSCLC: Impact of Comorbidities. Journal of Immunotherapy. 2021;44(5):198-203.
8. von Buttlar X, Reuss JE, Liu SV, Kim C. EML4-ALK rearrangement as a mechanism of resistance to osimertinib in metastatic lung adenocarcinoma: A Case report. JTO Clinical and Research Reports. 2021;2(6):100179.
9. Tlemsani C, Takahashi N, Pongor L, Rajapakse VN, Tyagi M, Wen X, Fasaye GA, Schmidt KT, Desai P, Kim C, Rajan A, Swift S, Sciuto L, Vilimas R, Webb S, Nichols S, Figg WD, Pommier Y, Calzone K, Steinberg SM, Wei JS, Guha U, Turner CE, Khan J, Thomas A. Whole-exome sequencing reveals germline-mutated small cell lung cancer subtype with favorable response to DNA repair-targeted therapies. Sci Transl Med. 2021;13(578). Epub 2021/01/29. doi: 10.1126/scitranslmed.abc7488. PubMed PMID: 33504652.
10. Sackstein P, Zaemes J, Kim C. Pembrolizumab-induced cytokine release syndrome in a patient with metastatic lung adenocarcinoma: a case report. J Immunother Cancer. 2021;9(7). Epub 2021/08/01. doi: 10.1136/jitc-2021-002855. PubMed PMID: 34330765; PMCID: PMC8327834.
11. Rehman M, Kim C, Reuss JE, Kiedrowski LA, Garg RJ, Liu SV. Divergent RET-and BRAF-Mediated Resistance to Osimertinib in EGFR-Mutant NSCLC: A Case Report. JCO Precision Oncology. 2021;5:939-42.
12. Peravali M, Joshi I, Ahn J, Kim C. A Systematic Review and Meta-Analysis of Clinical Characteristics and Outcomes in Patients With Lung Cancer with Coronavirus Disease 2019. JTO Clin Res Rep. 2021;2(3):100141. Epub 2021/01/14. doi: 10.1016/j.jtocrr.2020.100141. PubMed PMID: 33437971; PMCID: PMC7790456.
13. Peravali M, Ahn J, Chen K, Rao S, Veytsman I, Liu SV, Kim C. Safety and Efficacy of First-Line Pembrolizumab in Black Patients with Metastatic Non-Small Cell Lung Cancer. Oncologist. 2021. Epub 2021/04/13. doi: 10.1002/onco.13787. PubMed PMID: 33844354.
14. Nagasaka M, Singh V, Baca Y, Sukari A, Kim C, Mamdani H, Spira AI, Uprety D, Bepler G, Kim ES. The Effects of HER2 alterations in EGFR mutant non-small cell lung cancer. Clinical Lung Cancer. 2021.
15. Nagasaka M, Asad MFB, Al Hallak MN, Uddin MH, Sukari A, Baca Y, Xiu J, Magee D, Mamdani H, Uprety D, Kim C, Xia B, Liu SV, Nieva JJ, Lopes G, Bepler G, Borghaei H, Demeure MJ, Raez LE, Ma PC, Puri S, Korn WM, Azmi AS. Impact of XPO1 mutations on survival outcomes in metastatic non-small cell lung cancer (NSCLC). Lung Cancer. 2021;160:92-8. Epub 2021/09/06. doi: 10.1016/j.lungcan.2021.08.010. PubMed PMID: 34482103.
16. McGunigal M, Margolis M, Forsthoefel M, Singh T, Amarell K, Deblois D, Campbell L, Kim C, Liu S, Bergquist PJ. Thymic malignancies treated with active scanning proton beam radiation and Monte Carlo planning: early clinical experience. Acta Oncologica. 2021:1-4.
17. Kim C, Xi L, Cultraro CM, Wei F, Jones G, Cheng J, Shafiei A, Pham TH-T, Roper N, Akoth E. Longitudinal Circulating Tumor DNA Analysis in Blood and Saliva for Prediction of Response to Osimertinib and Disease Progression in EGFR-Mutant Lung Adenocarcinoma. Cancers. 2021;13(13):3342.
18. Kim C, Liu SV, Crawford J, Torres T, Chen V, Thompson J, Tan M, Esposito G, Subramaniam DS, Giaccone G. A Phase I Trial of Dasatinib and Osimertinib in TKI Naive Patients With Advanced EGFR-Mutant Non-Small-Cell Lung Cancer. Front Oncol. 2021;11:728155. Epub 2021/09/28. doi: 10.3389/fonc.2021.728155. PubMed PMID: 34568058; PMCID: PMC8457399.
19. Kareff SA, Samtani S, Burotto M, Prasad V, Kim C. Current Landscape of Immunotherapy Trials Involving the Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Axis in Intrathoracic Tumors. JTO Clinical and Research Reports. 2021;2(4):100149.
20. Judd J, Abdel Karim N, Khan H, Naqash AR, Baca Y, Xiu J, VanderWalde AM, Mamdani H, Raez LE, Nagasaka M, Pai SG, Socinski MA, Nieva JJ, Kim C, Wozniak AJ, Ikpeazu C, de Lima Lopes G, Jr., Spira AI, Korn WM, Kim ES, Liu SV, Borghaei H. Characterization of KRAS Mutation Subtypes in Non-small Cell Lung Cancer. Mol Cancer Ther. 2021. Epub 2021/09/15. doi: 10.1158/1535-7163.MCT-21-0201. PubMed PMID: 34518295.
21. Hsu R, Baca Y, Xiu J, Wang R, Bodor JN, Kim C, Khan H, Mamdani H, Nagasaka M, Puri S. Molecular characterization of Kita-Kyushu lung cancer antigen (KK-LC-1) expressing carcinomas. Oncotarget. 2021;12(25):2449.
22. Giaccone G, Kim C. Durable Response in Patients With Thymic Carcinoma Treated With Pembrolizumab After Prolonged Follow-Up. J Thorac Oncol. 2021;16(3):483-5. Epub 2020/11/29. doi: 10.1016/j.jtho.2020.11.003. PubMed PMID: 33248322.
23. Estrada-Bernal A, Le AT, Doak AE, Tirunagaru VG, Silva S, Bull MR, Smaill JB, Patterson AV, Kim C, Liu SV, Doebele RC. Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family Oncogenes. Clin Cancer Res. 2021;27(5):1463-75. Epub 2020/12/24. doi: 10.1158/1078-0432.CCR-20-3555. PubMed PMID: 33355298; PMCID: PMC7926264.
24. Dudnik E, Kareff S, Moskovitz M, Kim C, Liu SV, Lobachov A, Gottfried T, Urban D, Zer A, Rotem O. Real-world survival outcomes with immune checkpoint inhibitors in large-cell neuroendocrine tumors of lung. Journal for immunotherapy of cancer. 2021;9(2).
25. Zaemes J, Kim C. Immune checkpoint inhibitor use and tuberculosis: a systematic review of the literature. Eur J Cancer. 2020;132:168-75. Epub 2020/05/07. doi: 10.1016/j.ejca.2020.03.015. PubMed PMID: 32375103.
26. Taylor KL, Fallon S, Subramaniam D, Davis K, To C, Lobo T, Tercyak KP, Friberg J, Tynan M, Russell E, Ahmed W, Ponder MC, Cusaac L, Thompson J, Gardner K, Kim C, Weiner LM. Implementation of the Smoking Treatment and Recovery (STAR) program: healthy cancer survivorship through integrated tobacco control. J Cancer Surviv. 2020;14(1):53-8. Epub 2019/11/07. doi: 10.1007/s11764-019-00826-1. PubMed PMID: 31686365.
27. Roper N, Brown A-L, Wei JS, Pack S, Trindade C, Kim C, Restifo O, Gao S, Sindiri S, Mehrabadi F, Meskini RE, Ohler ZW, Maity TK, Venugopala A, Cultraro CM, Akoth E, Padiernos E, Chen H, Kesarwala A, Smart DK, Nilubol N, Rajan A, Piotrowska Z, Xi L, Raffeld M, Pachenko AR, Sahinalp C, Hewitt S, Hoang CD, Khan J, Guha U. Clonal Evolution and Heterogeneity of Osimertinib Acquired Resistance Mechanisms in EGFR Mutant Lung Cancer. Cell Reports Medicine. 2020;1(1).
28. Peravali M, Wang H, Kim C, Veytsman I. Combined Inhibition of EGFR and VEGF Pathways in Patients with EGFR-Mutated Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis. Curr Oncol Rep. 2020;22(12):119. Epub 2020/09/19. doi: 10.1007/s11912-020-00981-0. PubMed PMID: 32945977.
29. Li N, Guha U, Kim C, Ye L, Cheng J, Li F, Chia D, Wei F, Wong DT. Longitudinal Monitoring of EGFR and PIK3CA Mutations by Saliva-Based EFIRM in Advanced NSCLC Patients With Local Ablative Therapy and Osimertinib Treatment: Two Case Reports. Frontiers in oncology. 2020;10:1240.
30. Kim C, Liu SV, Subramaniam DS, Torres T, Loda M, Esposito G, Giaccone G. Phase I study of the (177)Lu-DOTA(0)-Tyr(3)-Octreotate (lutathera) in combination with nivolumab in patients with neuroendocrine tumors of the lung. J Immunother Cancer. 2020;8(2). Epub 2020/07/04. doi: 10.1136/jitc-2020-000980. PubMed PMID: 32616557; PMCID: PMC7333915.
31. Kareff SA, Lischalk JW, Krochmal R, Kim C. Abscopal effect in pulmonary carcinoid tumor following ablative stereotactic body radiation therapy: a case report. J Med Case Rep. 2020;14(1):177. Epub 2020/10/05. doi: 10.1186/s13256-020-02512-8. PubMed PMID: 33010806; PMCID: PMC7532944.
32. Farid S, Latif H, Nilubol C, Kim C. Immune Checkpoint Inhibitor-induced Fanconi Syndrome. Cureus. 2020;12(4):e7686. doi: 10.7759/cureus.7686.
33. Shah NJ, Al-Shbool G, Blackburn M, Cook M, Belouali A, Liu SV, Madhavan S, He AR, Atkins MB, Gibney GT, Kim C. Safety and efficacy of immune checkpoint inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or hepatitis C viral infection. J Immunother Cancer. 2019;7(1):353. Epub 2019/12/19. doi: 10.1186/s40425-019-0771-1. PubMed PMID: 31847881; PMCID: PMC6918622.
34. Desai S, Kim C, Veytsman I. Role of Anti-EGFR Targeted Therapies in Stage III Locally Advanced Non-small Cell Lung Cancer: Give or Not to Give? Curr Oncol Rep. 2019;21(9):84. Epub 2019/08/15. doi: 10.1007/s11912-019-0835-x. PubMed PMID: 31410582.
35. Cook MR, Kim C. Safety and Efficacy of Immune Checkpoint Inhibitor Therapy in Patients With HIV Infection and Advanced-Stage Cancer: A Systematic Review. JAMA Oncol. 2019;5(7):1049-54. Epub 2019/02/08. doi: 10.1001/jamaoncol.2018.6737. PubMed PMID: 30730549.
36. Al-Shbool G, Latif H, Farid S, Wang S, Ahn J, Giaccone G, Kim C. Publication Rate and Characteristics of Lung Cancer Clinical Trials. JAMA Netw Open. 2019;2(11):e1914531. Epub 2019/11/07. doi: 10.1001/jamanetworkopen.2019.14531. PubMed PMID: 31693119; PMCID: PMC6865260.
37. Giaccone G, Kim C, Thompson J, McGuire C, Kallakury B, Chahine JJ, Manning M, Mogg R, Blumenschein WM, Tan MT, Subramaniam DS, Liu SV, Kaplan IM, McCutcheon JN. Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study. Lancet Oncol. 2018;19(3):347-55. Epub 2018/02/06. doi: 10.1016/S1470-2045(18)30062-7. PubMed PMID: 29395863.
38. Valle L, Thomas J, Kim C, Szabo E, Brown GT, Citrin D, Rajan A. Hepatoid adenocarcinoma of the lung metastasizing to the tonsil. Mol Clin Oncol. 2017;6(5):705-7. Epub 2017/05/23. doi: 10.3892/mco.2017.1215. PubMed PMID: 28529745; PMCID: PMC5431682.
39. Gharwan H, Kim C, Thomas A, Berman A, Kim SA, Biassou N, Steinberg SM, Rajan A. Thymic epithelial tumors and metastasis to the brain: a case series and systematic review. Transl Lung Cancer Res. 2017;6(5):588-99. Epub 2017/11/09. doi: 10.21037/tlcr.2017.08.06. PubMed PMID: 29114474; PMCID: PMC5653528.
40. Del Rivero J, Kim C, Eid M, Ahlman MA, Nieman LK, Rajan A. Thymic Hyperplasia after Treatment of ACTH-Dependent Cushing's Syndrome Can Be Mistaken for a Thymic Epithelial Tumor. J Thorac Oncol. 2017;12(4):e29-e32. Epub 2016/11/21. doi: 10.1016/j.jtho.2016.11.2215. PubMed PMID: 27865872.
41. Blagoev KB, Wilkerson J, Burotto M, Kim C, Espinal-Dominguez E, Garcia-Alfonso P, Alimchandani M, Miettinen M, Blanco-Codesido M, Fojo T. Neutral evolution of drug resistant colorectal cancer cell populations is independent of their KRAS status. PLoS One. 2017;12(10):e0175484. Epub 2017/10/06. doi: 10.1371/journal.pone.0175484. PubMed PMID: 28981524; PMCID: PMC5628783.
42. Kim C, Zhang X, Chan AT, Sesso HD, Rifai N, Stampfer MJ, Ma J. Inflammatory biomarkers, aspirin, and risk of colorectal cancer: Findings from the physicians' health study. Cancer Epidemiol. 2016;44:65-70. Epub 2016/08/10. doi: 10.1016/j.canep.2016.07.012. PubMed PMID: 27504605; PMCID: PMC5821121.
43. Kim C, Rajan A, DeBrito PA, Giaccone G. Metastatic lymphoepithelioma-like carcinoma of the lung treated with nivolumab: a case report and focused review of literature. Transl Lung Cancer Res. 2016;5(6):720-6. Epub 2017/02/06. doi: 10.21037/tlcr.2016.11.06. PubMed PMID: 28149767; PMCID: PMC5233874.
44. Kim C, Prasad V. Strength of Validation for Surrogate End Points Used in the US Food and Drug Administration's Approval of Oncology Drugs. Mayo Clin Proc. 2016. Epub 2016/05/30. doi: 10.1016/j.mayocp.2016.02.012. PubMed PMID: 27236424; PMCID: PMC5104665.
45. Prasad V, Kim C, Burotto M, Vandross A. The Strength of Association Between Surrogate End Points and Survival in Oncology: A Systematic Review of Trial-Level Meta-analyses. JAMA Intern Med. 2015;175(8):1389-98. Epub 2015/06/23. doi: 10.1001/jamainternmed.2015.2829. PubMed PMID: 26098871.
46. Kim C, Prasad V. Cancer Drugs Approved on the Basis of a Surrogate End Point and Subsequent Overall Survival: An Analysis of 5 Years of US Food and Drug Administration Approvals. JAMA Intern Med. 2015;175(12):1992-4. Epub 2015/10/27. doi: 10.1001/jamainternmed.2015.5868. PubMed PMID: 26502403.
47. Kim C, Economou S, Amatruda TT, Martin JC, Dudek AZ. Prognostic significance of microscopic tumor burden in sentinel lymph node in patients with cutaneous melanoma. Anticancer Res. 2015;35(1):301-9. Epub 2015/01/01. PubMed PMID: 25550564.
48. Gummadi T, Zhang BY, Valpione S, Kim C, Kottschade LA, Mittapalli RK, Chiarion-Sileni V, Pigozzo J, Elmquist WF, Dudek AZ. Impact of BRAF mutation and BRAF inhibition on melanoma brain metastases. Melanoma Res. 2015;25(1):75-9. Epub 2014/11/27. doi: 10.1097/CMR.0000000000000133. PubMed PMID: 25426645.
49. Kim DH, Kim C, Ding EL, Townsend MK, Lipsitz LA. Adiponectin levels and the risk of hypertension: a systematic review and meta-analysis. Hypertension. 2013;62(1):27-32. Epub 2013/05/30. doi: 10.1161/HYPERTENSIONAHA.113.01453. PubMed PMID: 23716587; PMCID: PMC3729220.
50. Paik KH, Lee MK, Jin DK, Kang HW, Lee KH, Kim AH, Kim C, Lee JE, Oh YJ, Kim S, Han SJ, Kwon EK, Choe YH. Marked suppression of ghrelin concentration by insulin in Prader-willi syndrome. J Korean Med Sci. 2007;22(2):177-82. Epub 2007/04/24. doi: 10.3346/jkms.2007.22.2.177. PubMed PMID: 17449920; PMCID: PMC2693578.
Reviews or editorials in refereed journals
1. Jonna S, Reuss JE, Kim C, Liu SV. Oral Chemotherapy for Treatment of Lung Cancer. Frontiers in Oncology. 2020;10:793.
2. Friedlaender A, Kim C, Addeo A. Rethinking the optimal duration of immune checkpoint inhibitors in non-small cell lung cancer throughout the COVID-19 pandemic. Frontiers in Oncology. 2020;10:862.
3. Kim C, Liu S. First-line EGFR TKI therapy in non-small-cell lung cancer: looking back before leaping forward. Oxford University Press; 2019.
4. Kim C, Giaccone G. Precision oncology in non-small-cell lung cancer: opportunities and challenges. Nat Rev Clin Oncol. 2018;15(6):348-9. Epub 2018/03/31. doi: 10.1038/s41571-018-0008-0. PubMed PMID: 29599475.
5. Kim C, Giaccone G. MEK inhibitors under development for treatment of non-small-cell lung cancer. Expert Opin Investig Drugs. 2018;27(1):17-30. Epub 2017/12/09. doi: 10.1080/13543784.2018.1415324. PubMed PMID: 29216787.
6. Kim C, Giaccone G. The role of immune checkpoint blockade for treatment of thymic epithelial tumors—a delicate balance between efficacy and side effects2018.
7. Kim C, Hoang CD, Kesarwala AH, Schrump DS, Guha U, Rajan A. Role of Local Ablative Therapy in Patients with Oligometastatic and Oligoprogressive Non-Small Cell Lung Cancer. J Thorac Oncol. 2017;12(2):179-93. Epub 2016/10/27. doi: 10.1016/j.jtho.2016.10.012. PubMed PMID: 27780780.
8. Rajan A, Kim C, Heery CR, Guha U, Gulley JL. Nivolumab, anti-programmed death-1 (PD-1) monoclonal antibody immunotherapy: Role in advanced cancers. Hum Vaccin Immunother. 2016;12(9):2219-31. Epub 2016/05/03. doi: 10.1080/21645515.2016.1175694. PubMed PMID: 27135835; PMCID: PMC5027703.
9. Kim C, Giaccone G. Lessons learned from BATTLE-2 in the war on cancer: the use of Bayesian method in clinical trial design. Ann Transl Med. 2016;4(23):466. Epub 2017/01/17. doi: 10.21037/atm.2016.11.48. PubMed PMID: 28090522; PMCID: PMC5220042.